We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Von Hippel-Lindau Disease
Disease Spotlight
Interested in receiving weekly updates about Von Hippel-Lindau Syndrome?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Israel Gomy
Aug 30, 2019
The patient's clinical diagnosis is VHL type 2, which is compatible with the molecular diagnosis (missense mutation).
As there is predisposition to pheochromocytoma, I would highly recommend screening the patient's sister and niece with plasma metanephrines and cathecolamines.
We follow the recommended screening protocols published on VHL Alliance web site. Based on the published data, I found the screening schedule in VHL Alliance site serves as a rather reliable guidance. I do not believe the genotype and phenotype correlation based on the types of mutations or location of the mutations carries a significant weight on screening decisions, except a few recurrent pathogenic mutations with a good volume data and evidence to suggest otherwise. As far as the follow up and treatment decisions, (i.e. observation with imaging studies, biopsy, or excision) we rely on the physicians with experiences on hemangioblastoma, renal cell carcinoma, and pancreatic neuroendocrine tumor. For opportunities of systemic therapy, we would encourage patient to participate in clinical trials if possible.
Samantha Greenberg
Sep 03, 2019
Given the patient and sister age at diagnosis, I would follow VHLA guidelines and do eye exams in the 2 year old and start pheo screening when older. Regarding follow up plan, our GI oncology team would typically follow the NET, which may be an option for follow up.
Apr 18, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Israel Gomy
Aug 30, 2019
Xia Wang MD, PhD
Sep 03, 2019
Samantha Greenberg
Sep 03, 2019
Apr 18, 2024
Pending Moderator approval.